Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD
A novel formulation may prevent blood vessel growth and vascular leakage in the retina
Altos Biologics submits EMA Marketing Authorisation Application for aflibercept biosimilar ALT-L9
Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea
US FDA approves biosimilar aflibercept-mrbb (Ahzantive)
The drug is a biosimilar for aflibercept 2 mg (Eylea)
Espansione Group receives CE Mark approval for eye-light® photobiomodulation device
The flagship, light-based technology has received approval for applications in the anterior and posterior segments
European Commission grants Marketing Authorisation for bevacizumab gamma
The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)
United States FDA approves two aflibercept 2 mg biosimilars
The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen